• A Company Dedicated to Safe Therapeutic Modulation of Monoamine Neurotransmitter

  • Interim Report
    January – September 2021

Share

Initiator Pharma Numbers

  • Number of men affected by Erectile Dysfunction worldwide 150 million
  • Number of people worldwide that are diagnosed with Trigeminal Neuralgia every year: 150000
  • Men with Erectile Dysfunction who do not respond to drug therapy 40 %
Initiatorpharma-module-homepage-1-22102021

Initiator Pharma currently has a portfolio of four projects, of which two are in clinical development and two are in preclinical development.

CEO letter

The future looks very exciting, and our three clinical-stage programs will all have upcoming key value inflection points in the form of Phase 2 data read-outs over the next couple of years. As always, I look forward to keeping you informed on the clinical development of our portfolio.

Initiatorpharma-module-homepage-2-22102021

Mono-amine transporters is a unique class of proteins that are located just outside the synaptic cleft (peri-synaptically), transporting monoamine transmitter overflow from the synaptic cleft back to the cytoplasm of the pre-synaptic neuron.